WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
maximize
Machine translation
1. (WO1994028145) EXPRESSION OF UROKINASE PLASMINOGEN ACTIVATOR INHIBITORS
Note: Text based on automatic Optical Character Recognition processes. Please use the PDF version for legal matters

WHAT IS CLAIMED:

1. A method for producing a non-fucosylated polypeptide consisting essentially of the EGF-like domain of human urokinase-type plasminogen activator, said method comprising:
providing a yeast host transformed with an expression vector, said vector comprising a transcriptional promoter operably linked to an oligonucleotide encoding a huPAR antagonist polypeptide consisting essentially of the EGF-like domain of human urokinase-type plasminogen activator or an active analog thereof;
culturing said yeast host under conditions which promote expression of said polypeptide; and
isolating said polypeptide.

2. The method of claim 1, wherein said oligonucleotide further encodes a signal leader polypeptide operatively connected to said huPAR antagonist polypeptide or analog, operative in said host cell to direct secretion of the expressed polypeptide.

3. The method of claim 2, wherein said signal leader comprises yeast α-factor leader.

4. The method of claim 3 wherein said yeast α-factor leader is

S. cerevisiae α-factor leader.

5. The method of claim 1, wherein said host cell is
Saccharomyces cerevisiae.

6. The method of claim 1 , wherein said huPAR antagonist polypeptide consists essentially of huPAj^g.

7. A huPAR antagonist polypeptide composition comprising a non-fucosylated polypeptide consisting essentially of the EGF-like domain of human urokinase-type plasminogen activator or an active analog thereof.

8. The composition of claim 7, wherein said non-fucosylated polypeptide consists essentially of huPAj^g.

9. The composition of claim 7, further comprising a pharmaceutically acceptable excipient.

10. A method for treating a uPA-mediated disorder, said method comprising:
providing a composition comprising a non-fucosylated polypeptide consisting essentially of the EGF-like domain of human urokinase-type plasminogen activator or an active analog thereof; and
administering an effective amount of said composition to a patient having a uPA-mediated disorder.

11. The method of claim 10, wherein said polypeptide consists essentially of huPAj^g.

12. The method of claim 10, wherein said uPA-mediated disorder is selected from the group consisting of metastasis, inappropriate angiogenesis, and chronic inflammation.

13. The method of claim 12, wherein said uPA-mediated disorder is selected from the group consisting of Kaposi's sarcoma, diabetic retinopathy, and rheumatoid arthritis.

14. The method of claim 10, wherein said composition is administered by instillation in the eye.

15. A method for pre-enriching a monovalent phage display mixture prior to screening for binding to a target, comprising:
(a) providing a mixture of monovalent display phage and non-displaying phage, wherein said monovalent display phage display both a candidate peptide and a common peptide, wherein said common peptide is identical for each monovalent display phage, and wherein said candidate peptide is different for different monovalent display phage; and
(b) separating all phage displaying a common peptide from phage not displaying a common peptide.

16. The method of claim 15, wherein said candidate peptide is huPA 8 or an active analog or active portion thereof.

17. The method of claim 15, wherein said common peptide comprises an antibody epitope.

18. The method of claim 17, wherein said epitope comprises Glu-Ty r-Met-Pro-Met-Glu .

19. The method of claim 15, further comprising:
(c) contacting said separated phage displaying said common peptide with said target; and (d) separating phage which bind said target from phage which do not bind said target.

20. The method of claim 19, wherein said target comprises huPAR.